ABSTRACT
Most antiviral or immunomodulatory therapies investigated for use in patients with COVID-19 have failed to show any mortality benefit. Similar to the previous pandemics caused by respiratory viruses, the role and benefit of corticosteroids has been under debate in COVID-19–related pulmonary disease. In this consult, we discuss the evidence regarding the efficacy of corticosteroid use in hospitalized patients with COVID-19, including data from the first randomized controlled trial on this subject.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Kshitij Chatterjee, MD⇑
- Correspondence:
Kshitij Chatterjee, MD, Department of Pulmonary Medicine, A90, Respiratory Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195: chattek{at}ccf.org
- Abhishek Bhardwaj, MD
ABSTRACT
Most antiviral or immunomodulatory therapies investigated for use in patients with COVID-19 have failed to show any mortality benefit. Similar to the previous pandemics caused by respiratory viruses, the role and benefit of corticosteroids has been under debate in COVID-19–related pulmonary disease. In this consult, we discuss the evidence regarding the efficacy of corticosteroid use in hospitalized patients with COVID-19, including data from the first randomized controlled trial on this subject.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.